University of Iowa Pharmaceuticals (UIP) was recently featured in a Quad Cities newscast about Duchenne Muscular Dystrophy, a genetic disease that affects approximately one in 3,500 boys. UIP has a contract with Halo Therapeutics to manufacture HT100, a potential therapy for Duchenne. See the full story here.